L'Oréal Dermatological Beauty Pro is a digital community empowering healthcare professionals to improve their daily practice of dermatology through cutting-edge research, science and education on skin and hair care.
Revolutionizing acne treatment with phylobioma
- 5min
- Jul. 2023
- Supported by
Phylobioma is a natural active ingredient that provides a targeted solution for the treatment of skin with slight to moderate acne. It targets the four major components of acne pathophysiology: sebaceous gland activity modification, hyper-keratinization, microbiota modification, and inflammation. It also acts by inhibiting the proliferation of the IA1 phylotype of the bacterium c. acnes, which in recent studies has been shown to be an essential factor in the acne pathogenesis.
The bacterial species C. acnes is one of the major pathogenic factors contributing to the development of acne. As a result of the high quantity of sebum and the low oxygen concentration, the microcomedo is an environment favorable to the growth of the microorganism. Recent studies have identified several subtypes of C. acnes, called phylotypes, with variable degrees of virulence.1
In acne, a loss of C. acnes phylotype diversity with a shift to phylotype IA1 has been observed in sebaceous sites. The capacity of this phylotype to form biofilms is greater than the others. It has been described as the virulent phylotype associated with the development of acne lesions. The preponderance of C. acnes IA1 contributes to the pathogenesis of acne by causing many modifications in the pilosebaceous environment.2,3,4,5
Phylobioma is a natural active ingredient that comes from the pericarp of immature pomegranates. The fruit originates from Gabès, an oasis in Tunisia, and is harvested manually at the stage of immaturity required for biological efficacy. The extract of pericarps from immature pomegranates ensures biological efficacy through a complex mixture of polyphenols, resulting in the management of acne symptoms. Polyphenols are known for their strong antioxidant power and act by neutralizing free radicals. Its therapeutic efficacy was clinically demonstrated in adult volunteers with mild to moderate acne, with a significant reduction in lesion count and GEA score, the reference score for overall assessment of acne severity.
Phylobioma targets the four major components of acne pathophysiology.
Phylobioma is a natural active ingredient, the result of 7 years of research, now included in Effaclar DUO+M which revolutionizes the treatment of acne symptoms thanks to a comprehensive formula to act on all major acne factors.
*Normal human sebocytes (NHS) were seeded and incubated at 37°C for 4 days. They were then treated with a solution containing linoleic acid and testosterone for 24 hours. Phylobioma at 0,001% or 0,0003% was added or not 6 hours after treatment began.
The secretion of lipid droplets was analyzed by staining with the BODIPY™ probe and the autophagy marker LC3b was monitored by an immunocytology study.
**Normal human keratinocytes were seeded in inserts and incubated at 37°C for 9 days. On D9 and D10 SILABSKIN® RE preparations were or were not treated topically with a suspension of C. acnes for 2 hours. Excess bacterial suspension was removed by suction and SILABSKIN® RE preparations were or were not treated topically with a mixture of squalene/peroxidated squalene for 24 hours. PHYLOBIOMA at 0,006% or 0,010% was or was not applied to the suspension of C. acnes at the same time. The syntheses of cytokeratin 5 (CK5) and cytokeratin 16 (CK16) were analyzed by immunohistochemistry on D11 (CK5) and D14 (CK16). Thickness of the stratum corneum (SC) was measured by a histochemical study on D14.
***C. acnes bacterium was seeded in microplates in the presence or absence of a sub-inhibiting concentration of PHYLOBIOMA (0,010%). Microplates were incubated in anaerobic conditions at 37°C for 48 hours. Bacteria not having adhered were eliminated by suction and the biofilm was stained with crystal violet. After rinsing to eliminated by suction and the biofilm was stained with crystal violet. After rinsing to eliminate residual non-adherent bacteria, the crystal violet was solubilized in ethanol and quantified by spectrophotometry at 540 nm. The quantity of biofilm formed is proportional to crystal violet assayed in wells.
****Naïve T lymphocytes (TL) were isolated from peripheral blood mononuclear cells and seeded in a culture medium containing a mixture enabling the differentiation of naïve TL into Th17L. After 4 days of culture, the medium was discarded and replaced with a medium containing the differentiation mixture in the presence or absence of PHYLOBIOMA at 0,003% or 0,010% 48 hours after treatment with PHYLOBIOMA, the secretion of IL-17 was assayed by an ELISA assay.
The bacterial species C. acnes is one of the major pathogenic factors contributing to the development of acne. As a result of the high quantity of sebum and the low oxygen concentration, the microcomedo is an environment favorable to the growth of the microorganism. Recent studies have identified several subtypes of C. acnes, called phylotypes, with variable degrees of virulence.1
In acne, a loss of C. acnes phylotype diversity with a shift to phylotype IA1 has been observed in sebaceous sites. The capacity of this phylotype to form biofilms is greater than the others. It has been described as the virulent phylotype associated with the development of acne lesions. The preponderance of C. acnes IA1 contributes to the pathogenesis of acne by causing many modifications in the pilosebaceous environment.2,3,4,5
Phylobioma is a natural active ingredient that comes from the pericarp of immature pomegranates. The fruit originates from Gabès, an oasis in Tunisia, and is harvested manually at the stage of immaturity required for biological efficacy. The extract of pericarps from immature pomegranates ensures biological efficacy through a complex mixture of polyphenols, resulting in the management of acne symptoms. Polyphenols are known for their strong antioxidant power and act by neutralizing free radicals. Its therapeutic efficacy was clinically demonstrated in adult volunteers with mild to moderate acne, with a significant reduction in lesion count and GEA score, the reference score for overall assessment of acne severity.
Phylobioma targets the four major components of acne pathophysiology.
- It restores sebaceous gland activity to normal. It inhibits the secretion of lipids droplets by 77%. It shows the capacity to limit the production of lipids.*
Effect of Phylobioma on sebogenesis in differentiated sebocytes* control with Phylobioma (0,003%) - Phylobioma limits keratolytic activity. When Phylobioma is applied at 0,010%, it returns the thickness of the stratum corneum to normal.**
- It reduces C. acnes proliferation. Phylobioma has an antibacterial activity by limiting the growth of c. acnes phylotype IA1 and its capacity to form a biofilm.***
Visualization of the effect of Phylobioma on the formation of the biofilm of C. acnes IA1*** - At last, Phylobioma regulates the inflammatory responses of sebocytes, keratocytes, and Th17 lymphocytes.****
Phylobioma is a natural active ingredient, the result of 7 years of research, now included in Effaclar DUO+M which revolutionizes the treatment of acne symptoms thanks to a comprehensive formula to act on all major acne factors.
*Normal human sebocytes (NHS) were seeded and incubated at 37°C for 4 days. They were then treated with a solution containing linoleic acid and testosterone for 24 hours. Phylobioma at 0,001% or 0,0003% was added or not 6 hours after treatment began.
The secretion of lipid droplets was analyzed by staining with the BODIPY™ probe and the autophagy marker LC3b was monitored by an immunocytology study.
**Normal human keratinocytes were seeded in inserts and incubated at 37°C for 9 days. On D9 and D10 SILABSKIN® RE preparations were or were not treated topically with a suspension of C. acnes for 2 hours. Excess bacterial suspension was removed by suction and SILABSKIN® RE preparations were or were not treated topically with a mixture of squalene/peroxidated squalene for 24 hours. PHYLOBIOMA at 0,006% or 0,010% was or was not applied to the suspension of C. acnes at the same time. The syntheses of cytokeratin 5 (CK5) and cytokeratin 16 (CK16) were analyzed by immunohistochemistry on D11 (CK5) and D14 (CK16). Thickness of the stratum corneum (SC) was measured by a histochemical study on D14.
***C. acnes bacterium was seeded in microplates in the presence or absence of a sub-inhibiting concentration of PHYLOBIOMA (0,010%). Microplates were incubated in anaerobic conditions at 37°C for 48 hours. Bacteria not having adhered were eliminated by suction and the biofilm was stained with crystal violet. After rinsing to eliminated by suction and the biofilm was stained with crystal violet. After rinsing to eliminate residual non-adherent bacteria, the crystal violet was solubilized in ethanol and quantified by spectrophotometry at 540 nm. The quantity of biofilm formed is proportional to crystal violet assayed in wells.
****Naïve T lymphocytes (TL) were isolated from peripheral blood mononuclear cells and seeded in a culture medium containing a mixture enabling the differentiation of naïve TL into Th17L. After 4 days of culture, the medium was discarded and replaced with a medium containing the differentiation mixture in the presence or absence of PHYLOBIOMA at 0,003% or 0,010% 48 hours after treatment with PHYLOBIOMA, the secretion of IL-17 was assayed by an ELISA assay.
REFERENCES
1Platsidaki E, Dessinioti C. Recent advances in understanding Propionibacterium acnes ( Cutibacterium acnes) in acne. F1000Res. 2018;7:F1000 Faculty Rev-1953.
2Zhang N, Yuan R, Xin KZ, Lu Z, Ma Y. Antimicrobial Susceptibility, Biotypes and Phylotypes of Clinical Cutibacterium (Formerly Propionibacterium) acnes Strains Isolated from Acne Patients: An Observational Study. Dermatol Ther (Heidelb). déc 2019;9(4):735‑46.
3Saint-Jean M, Corvec S, Nguyen JM, Le Moigne M, Boisrobert A, Khammari A, et al. Adult acne in women is not associated with a specific type of Cutibacterium acnes. J Am Acad Dermatol. sept 2019;81(3):851‑2.
4Paugam C, Corvec S, Saint-Jean M, Le Moigne M, Khammari A, Boisrobert A, et al. Propionibacterium acnes phylotypes and acne severity: an observational prospective study. J Eur Acad Dermatol Venereol. sept 2017;31(9):e398‑9.
5Dagnelie MA, Montassier E, Khammari A, Mounier C, Corvec S, Dréno B. Inflammatory skin is associated with changes in the skin microbiota composition on the back of severe acne patients. Exp Dermatol. août 2019;28(8):961‑7.